Drug Profile
Lipustobart - Livzon Mabpharm
Alternative Names: Lipustobart; LZM-009Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Livzon Mabpharm
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Injection)
- 29 Nov 2021 Lipustobart licensed to Bright Peak Therapeutics worldwide for the treatment of Cancer
- 16 Nov 2021 Lipustobart is still in phase I trials for Solid tumours in USA